Haoxi Health Technology Limited Class A Ordinary Shares
Here’s whether Haoxi Health Technology Limited Class A Ordinary Shares (HAO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-93.29% over 10 days); RSI 5 — oversold; weak 1-year return of -99.9%; 3-month momentum negative (-99.9%); rising volume on a downtrend (distribution, 1.83x avg). Currently 99.9% off its 52-week high. Score: -7/7.
HAO is trading below its 200-day MA ($106.68) — a key warning sign the longer-term trend is under pressure. An RSI of 4.8 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -99.9% compares to +16.5% for SPY (trailed the market by 116.4%). The current 99.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.